Tag Archives: Michael Wiederhorn

Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC) and Moderna (NASDAQ: MRNA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Centene (CNC – Research Report) and Moderna (MRNA – Research Report) with bullish sentiments. Centene (CNC) Oppenheimer analyst Michael Wiederhorn maintained a

Amedisys (AMED) Receives a Rating Update from a Top Analyst

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys (AMED – Research Report) today and set a price target of $215.00. The company’s shares closed last Friday at $186.50. According to TipRanks.com, Wiederhorn is a top 100 analyst with

Oppenheimer Maintains Their Buy Rating on Addus Homecare (ADUS)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Addus Homecare (ADUS – Research Report) today and set a price target of $107.00. The company’s shares closed last Monday at $48.40, close to its 52-week low of $47.78. According to

Oppenheimer Maintains a Buy Rating on Addus Homecare (ADUS)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Addus Homecare (ADUS – Research Report) yesterday and set a price target of $107.00. The company’s shares closed last Monday at $89.55. According to TipRanks.com, Wiederhorn is a top 100 analyst

Community Health (CYH) Receives a Rating Update from a Top Analyst

In a report released today, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Community Health (CYH – Research Report), with a price target of $5.00. The company’s shares closed last Monday at $4.81, close to its 52-week high of

Oppenheimer Sticks to Its Buy Rating for Chemed (CHE)

In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Chemed (CHE – Research Report), with a price target of $535.00. The company’s shares closed last Monday at $491.58, close to its 52-week high of $494.76.